Skip to content
Government WA, Medical Health Aged Care

Thank You Premier McGowan

Pharmaceutical Society of Australia (PSA) < 1 mins read

30 May 2023

QUOTES ATTRIBUTABLE TO PHARMACEUTICAL SOCIETY OF AUSTRALIA, WA PRESIDENT LUSI SHEEHAN

I am saddened to hear of the retirement of West Australia Premier Mark McGowan this week.

Premier McGowan has supported pharmacists and the health care system through some of the most difficult challenges, including the COVID-19 pandemic. We sincerely thank him for his unwavering support and leadership during this time.

Under Premier McGowan’s leadership there has been strong investment into the health sector, including in regional health and mental health services, ensuring that services are accessible and available to all West Australians who need them.

PSA is proud to have supported the McGowan Government’s free influenza vaccine programs in 2022 and 2023 that have supported vaccine coverage across Western Australia.

McGowan’s commitment to improving the health and wellbeing of our state has undoubtedly improved the lives of all West Australians.

On behalf of pharmacists across Western Australia, I thank Premier McGowan for his leadership, and wish him the best for what comes next.

I look forward to continuing to work constructively with the Government and the next Premier to support the health of all West Australians.

 

ENDS

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.